Atjaunināt sīkdatņu piekrišanu

E-grāmata: Drugs, Addiction, and the Brain

4.27/5 (20 ratings by Goodreads)
(Professor Emeritus, University of Bordeaux and Neurocentre Magendie, Inserm, Bordeaux, France), (Senior Research Assistant, The Scripps Research Institute, La Jolla, CA, USA), (The Scripps Research Institute, La Jolla, CA, USA)
  • Formāts: PDF+DRM
  • Izdošanas datums: 12-Jul-2014
  • Izdevniecība: Academic Press Inc
  • Valoda: eng
  • ISBN-13: 9780123869593
  • Formāts - PDF+DRM
  • Cena: 80,21 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: PDF+DRM
  • Izdošanas datums: 12-Jul-2014
  • Izdevniecība: Academic Press Inc
  • Valoda: eng
  • ISBN-13: 9780123869593

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Drugs, Addiction, and the Brain explores the molecular, cellular, and neurocircuitry systems in the brain that are responsible for drug addiction. Common neurobiological elements are emphasized that provide novel insights into how the brain mediates the acute rewarding effects of drugs of abuse and how it changes during the transition from initial drug use to compulsive drug use and addiction. The book provides a detailed overview of the pathophysiology of the disease. The information provided will be useful for neuroscientists in the field of addiction, drug abuse treatment providers, and undergraduate and postgraduate students who are interested in learning the diverse effects of drugs of abuse on the brain.

  • Full-color circuitry diagrams of brain regions implicated in each stage of the addiction cycle
  • Actual data figures from original sources illustrating key concepts and findings
  • Introduction to basic neuropharmacology terms and concepts
  • Introduction to numerous animal models used to study diverse aspects of drug use.
  • Thorough review of extant work on the neurobiology of addiction

Papildus informācija

The most current and comprehensive volume on the market offering coverage of the molecular, cellular, and neurocircuitry systems in the brain responsible for drug addiction, suitable for advanced student readers and beyond, authored by the Director of the NIAAA.
Preface vii
1 What is Addiction?
Definitions of Addiction
1(19)
Neuroadaptational Views of Addiction
20(6)
Summary
26(1)
Suggested Reading
27(3)
2 Introduction to the Neuropsychopharmacology of Drug Addiction
The Central Nervous System
30(3)
Pharmacology for Addiction
33(2)
Pharmacokinetics
35(7)
Basic Neurobiology of Addiction
42(10)
Brain Structures and Functions Relevant to the Three Stages of the Addiction Cycle
52(10)
Neuroadaptational Summary
62(1)
Suggested Reading
63(4)
3 Animal Models of Addiction
Validation of Animal Models of Drug Addiction
67(1)
Animal Models of the Binge/Intoxication Stage of the Addiction Cycle
68(10)
Animal Models of the Withdrawal/Negative Affect Stage of the Addiction Cycle
78(5)
Animal Models of the Preoccupation/Anticipation Stage of the Addiction Cycle
83(5)
Animal Models of Vulnerability to Addiction
88(1)
Summary of Animal Models of Addiction
89(1)
Suggested Reading
90(3)
4 Psychostimulants
Definitions
93(2)
History of Psychostimulant Use
95(7)
Physiological Effects
102(1)
Behavioral Effects
102(3)
Medical Uses
105(1)
Pharmacokinetics
105(3)
Behavioral Mechanism of Action
108(1)
Use, Abuse, and Addiction
109(3)
Neurobiological Effects
112(17)
Summary
129(2)
Suggested Reading
131(2)
5 Opioids
Definitions
133(1)
History of Opioid Use
134(1)
Physiological Effects
135(1)
Behavioral Effects
136(1)
Medical Uses
136(3)
Pharmacokinetics
139(1)
Behavioral Mechanism of Action
140(2)
Use, Abuse, and Addiction
142(12)
Neurobiological Effects
154(16)
Summary
170(1)
Suggested Reading
171(2)
6 Alcohol
Definitions
173(2)
History of Alcohol Use
175(4)
Behavioral Effects
179(1)
Pharmacokinetics
180(2)
Use, Abuse, and Addiction
182(6)
Alcohol Toxicity
188(7)
Behavioral Mechanism of Action
195(1)
Neurobiological Effects
196(21)
Summary
217(1)
Suggested Reading
218(3)
7 Nicotine
Definitions
221(1)
History of Use
222(8)
Medical Use and Behavioral Effects
230(1)
Pharmacokinetics
231(1)
Use, Abuse, and Addiction
232(6)
Behavioral Mechanism of Action
238(1)
Neurobiological Effects
239(19)
Summary
258(1)
Suggested Reading
258(3)
8 Cannabinoids
Definitions
261(7)
History of Cannabinoid Use
268(1)
Medical Uses
269(2)
Behavioral Effects
271(2)
Pharmacokinetics
273(2)
Use, Abuse, and Addiction
275(12)
Behavioral Mechanism of Action
287(1)
Neurobiological Effects
288(18)
Summary
306(1)
Suggested Reading
307(3)
9 Medications for the Treatment of Addiction -- A Neurobiological Perspective Conceptual Approach for Understanding Current and Future Medications Development
310(25)
Effects of Known Medications on Animal Models of Addiction -- Reverse Validity (Rosetta Stone Approach)
316(6)
Novel Targets for Medication Development
322(6)
Human Laboratory Studies
328(3)
Individual Differences and Medication Development
331(1)
Clinical Trials -- Unique Challenges and Opportunities
331(1)
Summary
331(1)
Suggested Reading
332(3)
Index 335
George F. Koob, Ph.D., received his Bachelor of Science degree from Pennsylvania State University and his Ph.D. in Behavioral Physiology from The Johns Hopkins University. He was recently appointed (in 2014) as Director of the National Institute on Alcohol Abuse and Alcoholism (currently on a leave of absence as Professor at The Scripps Research Institute, Adjunct Professor in the Departments of Psychology and Psychiatry at the University of California San Diego, and Adjunct Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego). As an authority on drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 780 scientific papers. In collaboration with Dr. Michel Le Moal, he wrote the renowned book Neurobiology of Addiction (Elsevier, 2006). He was previously Director of the NIAAA Alcohol Research Center at The Scripps Research Institute, Consortium Coordinator for NIAAA's multi-center Integrative Neuroscience Initiative on Alcoholism, and Co-Director of the Pearson Center for Alcoholism and Addiction Research. He has trained 75 postdoctoral fellows and 11 predoctoral fellows. He is currently Editor-in-Chief of the journal Pharmacology Biochemistry and Behavior and Senior Editor for Journal of Addiction Medicine. Dr. Koob taught for 35 years in the Psychology Department at the University of California San Diego, including courses such as Drugs Addiction and Mental Disorders and Impulse Control Disorders, courses that regularly matriculated 400-500 students each. He also taught Contemporary Topics in Central Nervous System Pharmacology at the Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD for 9 years.

Dr. Koob's research interests have been directed at the neurobiology of emotion, with a focus on the theoretical constructs of reward and stress. He has made contributions to our understanding of the anatomical connections of the emotional systems and the neurochemistry of emotional function. Dr. Koob has identified afferent and efferent connections of the basal forebrain (extended amygdala) in the region of the nucleus accumbens, bed nucleus of the stria terminalis, and central nucleus of the amygdala in motor activation, reinforcement mechanisms, behavioral responses to stress, drug self-administration, and the neuroadaptation associated with drug dependence.

Dr. Koob also is one of the world's authorities on the neurobiology of drug addiction. He has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of drugs of abuse and more recently on the neuroadaptations of these reward circuits associated with the transition to dependence. He has validated key animal models for dependence associated with drugs of abuse and has begun to explore a key role of anti-reward systems in the development of dependence.

Dr. Koob's work with the neurobiology of stress includes the characterization of behavioral functions in the central nervous system for catecholamines, opioid peptides, and corticotropin-releasing factor. Corticotropin-releasing factor, in addition to its classical hormonal functions in the hypothalamic-pituitary-adrenal axis, is also located in extrahypothalamic brain structures and may have an important role in brain emotional function. Recent use of specific corticotropin-releasing factor antagonists suggests that endogenous brain corticotropin-releasing factor may be involved in specific behavioral responses to stress, the psychopathology of anxiety and affective disorders, and drug addiction.

Michael A. Arends received his Bachelor of Science degree from the University of California, San Diego. He is currently a Senior Research Assistant in the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute and has worked in the field of the neurobiology of drug addiction for 20 years. He is Managing Editor for the journals Pharmacology Biochemistry and Behavior and Journal of Addiction Medicine. He has been acknowledged for his editorial and research assistance in over 450 scientific publications, including books, book chapters, and journal articles. Michel Le Moal, M.D., is Professor Emeritus of Neuroscience at the University of Bordeaux, France. He graduated in Medicine (1962) in Philosophy-Sociology and Natural Science and then Neurology (1967) and Psychiatry (1968). He completed a Doctoral in Science at the University of Bordeaux in 1974. In parallel with his academic life in Bordeaux, he spent time as an Associate Researcher and Professor at Caltech (1974) and at The Salk Institute and The Scripps Research Institute. At both institutions, he worked on dopamine neuron electrophysiology and investigated the roles of brain CRF and dopamine systems in behavior and drug addiction. He research interests concern behavior and adaptive processes, their biological foundations, and experimental psychopathology, a discipline he promoted. The concept of individual vulnerability to behavioral pathologies has been at the center of his working hypothesis. Dr. Le Moal has been the founder and director of several research laboratories at the Centre National de la Recherche Scientifique (CNRS) and Institut National de la Sante et de la Recherche Medicale and finally the Magendie Institute for Neuroscience and Biological Psychiatry in Bordeaux, France. He is an elected Fellow of the French National Academy of Sciences.